Abstract It has been demonstrated that monoallelic PALB2 (Partner and Localizer of BRCA2) gene mutations predispose to familial breast cancer. Some of the families reported with germline PALB2 mutations presented male breast cancer as a characteristic clinical feature. Therefore, we wanted to investigate the contribution of germline PALB2 mutations in a set of 131 Spanish BRCA1/BRCA2-negative breast/ovarian cancer families with at least one male breast cancer case. The analysis included direct sequencing of all coding exons and intron/exon boundaries as well as a Multiplex Ligation-dependent Probe Amplification-based analysis of genomic rearrangements. For the first time we have identified a genomic rearrangement of PALB2 gene involving a large deletion from exon 7 to 11 in Electronic supplementary material The online version of this article
Introduction
Breast cancer with an autosomal dominant pattern of inheritance accounts for 5-10% of all breast cancer cases. Between 20 and 25% of inherited breast cancer can be traced to germline mutations in BRCA1 and BRCA2 genes.
Other genes participating in DNA damage response pathways such as CHEK2, ATM, and FANCJ/BRIP1 are also involved in familial breast cancer [1] .
The PALB2 (for ''partner and localizer of BRCA2'') gene encodes a protein that participates in genome maintenance through double strand break repair. PALB2 protein binds to the BRCA2 N-terminal end stabilizing it in key nuclear structures, which allows BRCA2 to function in DNA repair and at the S-phase checkpoint [2] . PALB2 co-localizes with BRCA2 being essential for key BRCA2 nuclear caretaker functions, implying that PALB2 could be also considered a tumor-suppressor gene [3] . Recent studies have shown that PALB2 not only interplay with BRCA2, but also mediates the interaction between BRCA1 and BRCA2 in the DNA-damage response [4] . BRCA1 acts in this complex as an upstream regulator of PALB2 and BRCA2 in the DNA-damage response and is important for targeting PALB2 and BRCA2 to DNA-damage sites [4] . PALB2 and BRCA2 act together to deliver RAD51, another DNA double strand break repair, to the chromosomal lesion to initiate DNA repair. Moreover, it has been recently shown that PALB2 binds DNA and physically interacts with RAD51 exerting a stimulatory effect on the ability of RAD51 to make D-loops [5] .
BRCA2 is also known as FANCD1, which is a Fanconi anemia protein. Biallelic mutations in BRCA2 and PALB2, respectively, underlie Fanconi anemia complementation groups FA-D1 and FA-N. However, clinical phenotype of these patients is strikingly different from that reported in classical Fanconi anemia [6] . In particular, FA-D1 and FA-N are associated with higher risks of solid childhood malignancies such as Wilms tumor and medulloblastoma, which occur very rarely in other subtypes of Fanconi anemia. Monoallelic PALB2 mutations have also been confirmed to cause moderate-penetrance breast cancer susceptibility [2] , accounting for about 1% of BRCA1/ BRCA2 negative familial and early breast cancer [7, 8, 9] . PALB2 is responsible for 1-2% of young breast cancer patients unselected for breast family history in Chinese and white South African populations [10, 11] .
To date, studies examining PALB2 gene in specific populations have been carried out, identifying recurrent mutations such as c.2323C[T (p.Q775X) in French Canadians [9] , c.1592delT (p.L531 fs) in Finnish [12] or c.751C[T (p.Q251X) in Chinese population [10] .
Recently, a potential connection between PALB2 truncating mutations and male breast cancer arose from several studies. Rahman et al. [6] detected that the prevalence of truncating mutations was higher in families with both male and female breast cancer (6.7%) than in families with only breast cancer cases in females (1%). Moreover, more recently Garcia et al. [7] analyzed PALB2 germline mutations in a cohort of 95 BRCA1/BRCA2-negative Spanish breast/ovarian cancer families, identifying only one frameshift alteration (c.1056_1057delGA; p.K353IfsX7). Interestingly, the mutation was detected in a family with a male breast cancer, further supporting that male breast cancer is a clinical characteristic feature of PALB2 autosomal dominant breast cancer syndromes.
The present study attempts to evaluate for the first time in the Spanish population, the contribution of germline PALB2 mutations in 131 BRCA1/BRCA2-negative highrisk breast/ovarian cancer families with at least one case of male breast cancer. 
Materials and methods

Patients
Index cases from 131 BRCA1/BRCA2 mutation-negative Spanish high-risk breast/ovarian cancer families with at least one male breast cancer case were screened for mutations within the entire coding sequence and splicing sites of PALB2 gene. Families were ascertained through 12 different Spanish centers (Supplementary Table 1 ). Clinical characteristics of the families are represented in Table 1 . The ethics committee approvals as well as informed consent from the patients were obtained for the study.
All index cases had been previously screened for point mutations and large rearrangement mutations in BRCA1 and BRCA2 genes and were found to be negative.
Mutation analysis of PALB2 gene DNA samples were obtained from peripheral blood leukocytes using standard procedures. The entire coding sequence of PALB2 along with flanking intron boundaries were amplified using primers designed with Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Primer sequences and melting temperatures are shown in Supplementary Table 2. A negative control was used in each PCR. PCR quality was checked on Agilent 2100 Expert Bioanalyzer (Agilent Technologies Inc. Santa Clara, CA USA). Then, PCR products were purified by ''Exosap-it'' (USB Corporation, Cleveland, Ohio) and bi-directional sequencing reaction was performed with ''Big Dye Terminator v3.1 Cycles Sequencing Kit'' (Applied Byosistems, Warrington, UK) on ABI PRISM 3730xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) in accordance with the manufacturer's instructions. Sequences were performed using the PCR primers with the exception of exon 13 (see Supplementary Table 2 ). Sequences were examined using Staden Package software (Open Source Technology Group, Inc).
Multiplex ligation-dependent probe amplification (MLPA) to detect genomic rearrangements of PALB2 was performed using the FANCD2-PALB2 kit (P057) from MRCHolland (Amsterdam, The Netherlands) in accordance with the manufacturer's protocol. The samples were run and analyzed on the ABI PRISM 3730xl Genetic Analyzer (Applied Biosystems) using fragment analysis tools. Analysis was repeated using an independent sample in an independent assay for positive DNA samples of a genomic rearrangement. Analysis of MLPA results was performed visually and by Coffalyser MLPA-DAT from MRC-Holland using direct analysis as analysis method to normalization.
In silico analysis
In brief, splicing predictions were performed with SpliceSiteFinder [13] , MaxEntScan [14] , NNSplice [15] , and GeneSplicer [16] algorithms. Biological significance was suspected only if two algorithms predicted a splice site score variation greater than 10% [17] . Amino acid substitutions were tested with PolyPhen-2 
Results
We sequenced all exons and intronic boundaries of PALB2 gene and we also carried out MLPA analysis in 131 index cases from BRCA1/BRCA2-negative high-risk Spanish breast/ovarian cancer families with at least one male breast cancer.
We identified a large deletion spanning from exon 7 to 11 (c.2587-?_3201 ? ?del) (Fig. 1) , in a woman diagnosed with breast cancer at 70 years of age. The proband had a brother diagnosed both with breast cancer at 75 years and gastric cancer after the initial breast cancer diagnosis (Fig. 2) . To confirm segregation with disease, we tested for the presence of the PALB2 deletion in the paraffined breast tumoral sample of the affected brother. MLPA analysis demonstrated the presence of the alteration. Interestingly, we observed a dosage reduction close to 75% for exons 7 to 11 together with a dosage reduction in the 25-50% range for the remaining exons (the only exception being exon 1, in which no dosage reduction was observed). The data might be compatible with partial loss of the wild type allele (exons 2 to 13) in the tumor (Fig. 1) .
In addition to this deletion, we also identified seventeen PALB2 germline variants, although none of them was predicted to result in a truncated protein product ( Table 2) . Seven of them were novel (c. [7, 10, 12, [19] [20] [21] [22] [23] .
The results of bioinformatic predictions for intronic and missense variants are represented in Table 3 In order to identify if these six variants were inherited together, co-segregation analysis in one of the carrier families was performed. Our results suggest that all the six variants constituted a haplotype (Supplementary Figure 1) that is present in the two breast cancer patients of the analyzed family.
Discussion
PALB2 mutations have recently been shown to confer a moderate risk to develop breast cancer [6] . It has been reported that families carrying protein-truncating PALB2 mutations shown cases of male breast cancer [6, 7] . Given Table 3 Results of bioinformatic analysis for PALB2 the increased risk of male breast cancer associated with carrying a germline BRCA2 mutation and the functional relationship between BRCA2 and PALB2, the male PALB2 mutation carriers might be at an increased risk of breast cancer. Until now more than 26 PALB2 truncating mutations have been reported [20, 22, [24] [25] [26] , 22 of them found in breast cancer families. Although large genomic rearrangements in PALB2 have been analyzed in studies of familial breast cancer [9, 20, 27, 28] , the unique large genomic mutation detected in PALB2 was c.71-?_561 ? ?del. This genomic change was identified in a Fanconi Anemia patient, and it implies the deletion of exons 2, 3, and 4 [29] . In our series of 131 index cases from Spanish BRCA1/ BRCA2-negative breast/ovarian cancer families with a male breast cancer case, we identified a large rearrangement in one breast cancer index case. The mutation c.2587-?_3201 ? ?del detected in our population is a large deletion comprising exons 7 to 11. Our finding provides the first evidence that large genomic changes in PALB2 also contribute to hereditary breast cancer in families BRCA1/ BRCA2 negatives.
To date, all PALB2 mutations reported as pathogenic result in premature protein truncation [6] , and were identified in about 1% of familial breast cancer. In breast cancer families with both female and male breast cancer cases, frequency of PALB2 mutations increased to 6.7% (1/15) in the UK series of Rahman et al. [6] and to 9% (1/11) in the Spanish series of Garcia et al. [7] . Although these previous series of families with male breast cancer were small, results seemed to suggest a higher implication of PALB2 mutations within this type of families. In the present study, we analyzed 131 Spanish female and male breast cancer families extending the mutation detection analysis to detect large genomic rearrangements of PALB2 by using Multiplex ligation-dependent probe amplification (MLPA). The frequency of PALB2 mutations found was 0.75%, which is similar to the 1% frequency previously reported for breast cancer families not selected for male breast cancer. However, we cannot rule out the potential pathogenicity of non truncating PALB2 variants. It has been shown that the N-terminal coiled-coil motif of PALB2 (residues 1-319) interacts with the coiled-coil domain of BRCA1 [4, 30] , whereas the C-terminal WD40 repeats of PALB2 (residues 836-1186) associate with the N-terminus of BRCA2 [3, 4, 31] . Thus, PALB2 missense variants in these domains might be pathogenic. (Table 3) .
As for other genes, the possibility of intronic variants of PALB2 being implicated in the splicing process should not be discarded. Besides, functional analysis for variants that could regulate gene expression should also being considered.
The MLPA analysis of the breast tumor sample FFPE tissue from the carrier of exon 7-11 deletion suggests partial loss of the wild type PALB2 allele (exons 2 to 13) which in turns could support previous evidences that PALB2 loss of function might also conform to the inactivation model of a classic tumor-suppressor gene [7] . Yet, great caution should be taken when interpreting MLPA analysis of FFPE tissue.
In summary, our study identifies for the first time a genomic rearrangement of PALB2 gene in a BRCA1/ BRCA2 mutation-negative Spanish cancer family with at least one male breast cancer case. If we considered only PALB2 truncation variants as pathogenic, the frequency of PALB2 mutations in high-risk families with male breast cancer is similar to that reported for high-risk families not selected by the presence of male breast cancer. However, more studies to assess the implication of PALB2 variants that do not originate PALB2 truncation (missense changes, small in-frame insertions or deletions and potential splice site alterations) are required.
